GlobeNewswire

CloudCraze Continues 2017 Momentum, Empowers Customers to Blaze New Trails With B2B Commerce

Dela

Customers across manufacturing, software and consumer goods industries launch new business buyer journeys with B2B commerce on the Salesforce Platform

SAN FRANCISCO, Nov. 02, 2017 (GLOBE NEWSWIRE) -- CloudCraze, an enterprise B2B commerce platform, has experienced significant momentum in B2B commerce, leveraging $20 million in funding and several major product releases to empower customers to blaze new trails. CloudCraze customers, Symantec, Univar, WABCO and others will speak to the transformative effect commerce has had for their businesses at Dreamforce 2017.

CloudCraze started 2017 off strong with a $20 million investment from Insight Venture Partners and Salesforce Ventures. This funding helped drive two major product releases that allow customers to get the most out of their CloudCraze and Salesforce investments. Recognition in The Forrester Wave(TM): B2B Commerce Suites, Q1 2017The Forrester Wave(TM): B2B Commerce Suites For Midsize Organizations, Q3 2017, and The Gartner Magic Quadrant for Digital Commerce 2017 reinforces the value CloudCraze provides companies in the manufacturing, CPG and software industries.

"CloudCraze's trailblazing investments in digital innovation have helped our customers forge their B2B commerce paths and drive lasting change," said Chris Dalton, CEO of CloudCraze. "Whether they're embarking on B2B commerce for the first time, upgrading to cloud commerce, or launching a new business model, CloudCraze customers have the necessary tools to adapt and scale with the rapidly evolving B2B industry. We're excited to show Dreamforce 2017 attendees the transformative power of commerce on Salesforce."

CloudCraze's commerce innovation has enabled some of the world's iconic brands to maximize their growth potential through B2B commerce. This year's product releases have included enhanced subscription services, advanced merchandising, Salesforce Lightning components and robust APIs for platform flexibility. Built on the Salesforce Platform, CloudCraze gives customers unique access to a 360-degree view of the customer, fast speed to revenue and reduced costs.

At Dreamforce 2017, Symantec, Univar, WABCO and others will present their experience working with CloudCraze and the value its native Salesforce Platform has provided to drive innovation, enhance customer engagement, and increase revenue. Visit the CloudCraze Dreamforce page for details on session dates, times and speakers.

CloudCraze is a Gold sponsor at Dreamforce 2017, the most inspiring technology event of the year and the world's largest gathering of Trailblazers. CloudCraze is exhibiting at booth #317 and will have an industry kiosk in the Manufacturing Campground of the Dreamforce Customer Success Expo, showcasing its product innovation through demonstrations and customer use cases.

For more information on CloudCraze's presence at Dreamforce 2017, visit CloudCraze at Dreamforce.

Salesforce, Dreamforce and others are among the trademarks of salesforce.com, inc.

About CloudCraze
CloudCraze delivers robust B2B commerce, built on the Salesforce Platform. It allows businesses to generate online revenue fast and easily scale for growth. Its Customer-First Commerce model puts the customer at the core, informing every interaction with data across commerce, sales, marketing, service and more. With the trusted Salesforce infrastructure and core capabilities, CloudCraze provides flexibility to extend functionality, add products and channels, and conduct billions of dollars in transactions anywhere. CloudCraze powers Customer-First Commerce for industry leaders such as AB InBev, Coca-Cola, Ecolab, GE, Hallmark, Kaplan, Kellogg's Land O'Lakes, L'Oreal, Symantec, Tyco.

CloudCraze is recognized as a Visionary in the Gartner Magic Quadrant for Digital Commerce 2017, and a Strong Performer in The Forrester Wave: B2B Commerce Suites, Q1 2017 and The Forrester Wave: B2B Commerce Suites for Midsize Organizations, Q3 2017. CloudCraze is a Salesforce Platinum ISV Partner.

Media Contacts
Rachel Gulden
Senior Account Executive
rachel.gulden@walkersands.com
312.267.0530

Sarah Traxler
Senior Director, Marketing
sarah.traxler@cloudcraze.com
866.217.3210




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CloudCraze via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum